AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 151 min read$ULBI

ULBI Q3'26 Earnings: revenue estimate is 56.00M USD

Ultralife Corporation (ULBI) will report Q3'26 earnings on October 22. Analysts expect revenue of $56.00M and EPS of $0.23. Results are anticipated at 8:00 AM ET.

Original reporting
tradingview.com
Published Oct 15, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ULBI Q3'26 Earnings: revenue estimate is 56.00M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$ULBINeutralMed
01

Why it matters

The earnings preview introduces new guidance, which may trigger short‑term trading activity.

02

Market read

Guidance release is the primary catalyst for ULBI's near‑term price action.

03

What to watch

Potential supply chain constraints or regulatory approvals could affect performance beyond the guidance.

Relevance 6/10Novelty 7/10Timing: pre‑market on Oct 22

Background

Ultralife Corp. is a small-cap medical device company; the article previews its upcoming Q3 earnings.

Company-level read

Ticker impact

$ULBINeutralMedium confidence
Context

Q3'26 earnings preview with revenue estimate of $56M and EPS $0.23 to be released on Oct 22.

Expected impact

likely modest pressure or bounce as market prices in the new guidance

Evidence & confidence

Small-cap earnings guidance often leads to limited volatility; the numbers are new but modest in scale.

Market effects

Sector

Provides a data point for the medical device/healthcare equipment sector.

Regional

Limited to US small‑cap investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

Guidance may be overly optimistic; actual results could miss expectations, prompting a sell‑off.

Key entities

  • Company
    Ultralife Corporation

    US-listed medical device manufacturer (NASDAQ: ULBI).

Read at source← All news

Related articles

OCT 27
$ENSHighAI 9/10

EnerSys to Acquire Ultralife for $16 Per Share in Cash

EnerSys (ENS) agreed to acquire Ultralife for $16 per share in cash. The deal, subject to regulatory approvals, includes support from shareholders holding 40.3% of Ultralife's shares. The tender offer is expected to start within 10 business days and may close by April 27, 2027, with possible extensions.

tradingview.com1 min
OCT 27
$ENSHighAI 9/10

EnerSys to acquire Ultralife for $320 million in cash

EnerSys (ENS) agreed to acquire Ultralife (ULBI) for $320 million in cash, including debt. Ultralife shareholders will receive $16.00 per share, a 166% premium over Monday's closing price. The deal, approved by both boards, is expected to close in Q1 2027. EnerSys will finance the acquisition with available cash. Both companies' CEOs cited strategic benefits and value creation.

investing.com2 min
AUG 8
$ULBIMedAI 8/10

Ultralife (ULBI) Q2 2026 Earnings Call Transcript

Ultralife (ULBI) reported Q2 FY2026 revenue of $47.9 million, down 1.3% year over year, with GAAP EPS of $0.15. Gross margin rose to 28.9% on a 500 bps increase, aided by a $1.1 million IEEPA tariff refund. Backlog hit a record $117.5 million, up 39% from a year earlier, and July backlog neared $130 million.

fool.com6 min
AUG 7
$ULBIMed

Ultralife Corporation Reports Second Quarter Results

ULTRALIFE CORP (ULBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results: ● Sales of $47.9 million compared to $48.6 mil

SEC EDGAR 8-K6 min